Table 1.

Definition of multiple myeloma based on 2014 IMWG criteria.

Criteria for Multiple Myeloma:
Clonal bone marrow plasma cells ≥10% or biopsy-proven bony or extramedullary plasmacytoma and any one or more of the following myeloma defining events:
1) Evidence of end organ damage that can be attributed to the underlying plasma cell proliferative disorder, specifically:
• Hypercalcaemia: serum calcium >0·25 mmol/L (>1 mg/dL) higher than the upper limit of normal or >275 mmol/L (>11 mg/dL)
• Renal insufficiency: creatinine clearance <40 mL per min† or serum creatinine>177 μmol/L (>2 mg/dL)
• Anaemia: haemoglobin value of >20 g/L below the lower limit of normal, or a haemoglobin value <100 g/L
• Bone lesions: one or more osteolytic lesions on skeletal radiography, CT, or PET-CT
2) Any one or more of the following biomarkers of malignancy
• Clonal bone marrow plasma cell percentage≥60%
• Involved:uninvolved serum free light chain ratio≥100
• >1 focal lesions on MRI study
Definition of smoldering multiple myeloma:
1) Serum monoclonal protein (IgG or IgA) ≥30 g/L or urinary monoclonal protein ≥500 mg per 24 h and/or clonal bone marrow plasma cells 10–60%
2) Absence of myeloma defining events or amyloidosis